Macro­Gen­ics, Ab­b­Vie stop de­vel­op­ment of part­nered ADC

Macro­Gen­ics and Ab­b­Vie plan to end de­vel­op­ment of their ADAM9-tar­get­ed an­ti­body-drug con­ju­gate af­ter ear­ly tri­al da­ta dis­ap­point­ed.

The Mary­land-based Macro­Gen­ics said the ADC, known as IMGC936, “did not achieve pre-es­tab­lished clin­i­cal safe­ty and ef­fi­ca­cy bench­marks.”

Im­muno­Gen had led the clin­i­cal de­vel­op­ment of IMGC936 and com­plet­ed the Phase I stud­ies. Ab­b­Vie bought the ADC drug­mak­er for $10.1 bil­lion in No­vem­ber. Im­muno­Gen and Macro­Gen­ics had a 50/50 col­lab­o­ra­tion on the as­set.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.